Mutations of KRAS, CDKN2a, TP53, and SMAD4, which are driver mutations in pancreatic cancers, accumulate according to the histological grade of PanINs and drive neoplastic transformation and tumor progression [6,7]. This evidence concerns the gene KRAS and pancreatic neoplasm.